Celcuity Inc. CELC
We take great care to ensure that the data presented and summarized in this overview for Celcuity Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CELC
View all-
Baker Bros. Advisors LP New York, NY5.45MShares$299 Million0.74% of portfolio
-
Bvf Inc San Francisco, CA3.47MShares$190 Million1.82% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.01MShares$165 Million3.12% of portfolio
-
Nea Management Company, LLC Timonium, MD2.29MShares$126 Million2.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.67MShares$91.6 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY1.63MShares$89.7 Million0.96% of portfolio
-
Black Rock Inc. New York, NY1.46MShares$80.1 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA1.39MShares$76.3 Million0.35% of portfolio
-
Saturn V Capital Management LLC Austin, TX1.19MShares$65.1 Million6.41% of portfolio
-
Braidwell LP Stamford, CT884KShares$48.6 Million0.72% of portfolio
Latest Institutional Activity in CELC
Top Purchases
Top Sells
About CELC
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at CELC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2025
|
Richard Nigon |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
7,917
+3.56%
|
$55,419
$7.56 P/Share
|
|
Sep 08
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
170,100
+1.03%
|
$9,695,700
$57.12 P/Share
|
|
Sep 02
2025
|
Brian F. Sullivan Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
104,340
+7.08%
|
$834,720
$8.05 P/Share
|
|
Jul 28
2025
|
David Dalvey |
SELL
Open market or private sale
|
Indirect |
100,000
-13.29%
|
$4,400,000
$44.75 P/Share
|
|
Jul 28
2025
|
David Dalvey |
SELL
Open market or private sale
|
Direct |
9,325
-66.97%
|
$419,625
$45.22 P/Share
|
|
May 27
2025
|
Richard E Buller |
BUY
Bona fide gift
|
Indirect |
1,079
+12.21%
|
-
|
|
May 27
2025
|
Richard E Buller |
SELL
Bona fide gift
|
Direct |
1,079
-51.19%
|
-
|
|
May 19
2025
|
Richard E Buller |
BUY
Grant, award, or other acquisition
|
Direct |
1,029
+32.8%
|
-
|
|
Apr 14
2025
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Direct |
8,155
+0.64%
|
-
|
|
Apr 14
2025
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
8,155
-100.0%
|
-
|
|
Mar 04
2025
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
36,845
+4.39%
|
-
|
|
Mar 04
2025
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
36,845
-81.88%
|
-
|
|
Mar 03
2025
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
84,670
+27.01%
|
-
|
|
Mar 03
2025
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
84,670
-3.2%
|
-
|
|
Dec 02
2024
|
Leo Furcht |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+2.27%
|
$750
$3.6 P/Share
|
|
Oct 23
2024
|
Richard E Buller |
SELL
Open market or private sale
|
Indirect |
350
-4.98%
|
$5,600
$16.25 P/Share
|
|
Aug 23
2024
|
Richard E Buller |
SELL
Open market or private sale
|
Indirect |
350
-4.74%
|
$5,600
$16.95 P/Share
|
|
Aug 20
2024
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Direct |
189,103
+12.35%
|
-
|
|
Aug 20
2024
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
189,103
-100.0%
|
-
|
|
Jun 21
2024
|
Richard E Buller |
SELL
Open market or private sale
|
Indirect |
350
-4.53%
|
$5,250
$15.68 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 170K shares |
|---|---|
| Grant, award, or other acquisition | 1.03K shares |
| Bona fide gift | 131K shares |
| Exercise of in-the-money or at-the-money derivatives securities | 112K shares |
| Exercise of conversion of derivative security | 250 shares |
| Bona fide gift | 131K shares |
|---|---|
| Open market or private sale | 110K shares |